Abstract:Rationale: Current therapies for metastatic osseous disease frequently fail to provide a durable treatment response. To date, there are only limited therapeutic options for metastatic prostate cancer, the mechanisms that drive the survival of metastasis-initiating cells are poorly characterized, and reliable prognostic markers are missing. A high aldehyde dehydrogenase (ALDH) activity has been long considered a marker of cancer stem cells (CSC). Our study characterized a differential role of ALDH1A1 and ALDH1A3 genes as regulators of prostate cancer progression and metastatic growth. Methods: By genetic silencing of ALDH1A1 and ALDH1A3 in vitro, in xenografted zebrafish and murine models, and by comparative immunohistochemical analyses of benign, primary tumor, and metastatic specimens from patients with prostate cancer, we demonstrated that ALDH1A1 and ALDH1A3 maintain the CSC phenotype and radioresistance and regulate bone metastasis-initiating cells. We have validated ALDH1A1 and ALDH1A3 as potential biomarkers of clinical outcomes in the independent cohorts of patients with PCa. Furthermore, by RNAseq, chromatin immunoprecipitation (ChIP), and biostatistics analyses, we suggested the molecular mechanisms explaining the role of ALDH1A1 in PCa progression. Results: We found that aldehyde dehydrogenase protein ALDH1A1 positively regulates tumor cell survival in circulation, extravasation, and metastatic dissemination, whereas ALDH1A3 plays the opposite role. ALDH1A1 and ALDH1A3 are differentially expressed in metastatic tumors of patients with prostate cancer, and their expression levels oppositely correlate with clinical outcomes. Prostate cancer progression is associated with the increasing interplay of ALDH1A1 with androgen receptor (AR) and retinoid receptor (RAR) transcriptional programs. Polo-like kinase 3 (PLK3) was identified as a transcriptional target oppositely regulated by ALDH1A1 and ALDH1A3 genes in RAR and AR-dependent manner. PLK3 contributes to the control of prostate cancer cell proliferation, migration, DNA repair, and radioresistance. ALDH1A1 gain in prostate cancer bone metastases is associated with high PLK3 expression. Conclusion: This report provides the first evidence that ALDH1A1 and PLK3 could serve as biomarkers to predict metastatic dissemination and radiotherapy resistance in patients with prostate cancer and could be potential therapeutic targets to eliminate metastasis-initiating and radioresistant tumor cell populations.

Effects of ALK1Fc Treatment on Prostate Cancer Cells Interacting with Bone and Bone Cells in Bone Metastasis Models.

ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models

Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors

Biological Roles of Human Bone Morphogenetic Protein 9 in the Bone Microenvironment of Human Breast Cancer MDA-MB-231 Cells.

Anti-Human Activin Receptor-Like Kinase 1 (alk1) Antibody Attenuates Bone Morphogenetic Protein 9 (Bmp9)-Induced Alk1 Signaling and Interferes with Endothelial Cell Sprouting

Constitutive Activation of Activin Receptor-like Kinase 2 in Human Breast Cancer Cells inhibits Metastatic Progression and Osteolytic Bone Lesions

ABL Kinases Promote Breast Cancer Osteolytic Metastasis by Modulating Tumor-Bone Interactions Through TAZ and STAT5 Signaling

ALK: a tyrosine kinase target for cancer therapy

Abstract 1370: Activin Receptor-Like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors

Genetic and Pharmacological Targeting of Activin Receptor-Like Kinase 1 Impairs Tumor Growth and Angiogenesis

Inactivation of ABL kinases suppresses non-small cell lung cancer metastasis.

Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease

Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy

BMP-9 Signals Via ALK1 and Inhibits Bfgf-Induced Endothelial Cell Proliferation and VEGF-stimulated Angiogenesis

ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription

Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms

An ALK1-governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases

Targeting Tumour Vasculature by Inhibiting Activin Receptor-Like Kinase (alk)1 Function

Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer

Abstract 2844: BMP inhibition overcomes chemoresistance of prostate cancer

BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo